COVID-19 guidance: research and development
The joint document aimed to make it easier for developers to submit paediatric development plans simultaneously to the regulators, to help speed up the development and approval of COVID-19 treatments and vaccines.
EMA and the FDA encouraged medicine developers to submit PIPs and iPSPs early.
EMA and the FDA published the joint document on 2 June 2020.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
